MK

Merck KGaA

Every trial this sponsor leads in the registry, and everything it has published.

405All trials
Recruiting13
Recruited11
Completed293
Stopped88

24 active · 6% of this sponsor’s registry footprint

Oncology16 trials
Immunology & Inflammation3 trials
Neurology2 trials
Gastroenterology & Hepatology1 trial
Womens Health1 trial

Not shown above: 1 Phase 1 healthy-volunteer trial.

Trials by phase

Phase 1160
Phase 295
Phase 387
Phase 459
Unphased4

Pipeline by phase · 16 drugs in active development

Phase 3 · 5 drugs

Precemtabart Tocentecan (M9140)4 trials · 1 recruitingest. Sept 2026
Enpatoran3 trials · 2 recruitingest. Aug 2028
Avelumab2 trials
Cetrorelix1 trial · 1 recruitingest. Jul 2028
Cladribine Low Dose1 trial · 1 recruitingest. Aug 2028

Phase 2 · 3 drugs

Mirdametinib2 trials · 1 recruitingest. Oct 2026
Pimicotinib1 trial · 1 recruitingest. Nov 2029
Tepotinib1 trial

Phase 1 · 7 drugs

M03241 trial · 1 recruitingest. Feb 2029
M35541 trial · 1 recruitingest. Apr 2027
M55421 trial · 1 recruitingest. Nov 2026
M74371 trial · 1 recruitingest. Sept 2028
M94661 trialest. Feb 2027
SW-6821 trial · 1 recruitingest. Jan 2027
Tuvusertib (M1774)1 trialest. Nov 2026

Phase 4 · 1 drug

Nirogacestat2 trials · 1 recruitingest. May 2027

Active trials only, code names and brands merged. 293 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 2 of 10 curated

Non-small cell lung cancer (Oncology)4 trials · 1 recruiting · 4 drugs0.3% of landscape
Breast cancer (Oncology)1 trial · 1 recruiting · 1 drug<0.1% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon